Pergolide: Treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). Longterm follow up on pergolide

Journal of Neural Transmission

Volumn 105, Issue 2-3, 1998, Pages 265-268

  Staedt, J ^a   Hunerjager H ^a   Ruther E ^a   Stoppe, G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Longterm treatment; NMS; Nocturnal myoclonus syndrome; Pergolide; Restless legs syndrome; RLS

Indexed keywords

ANTIPARKINSON AGENT; DECARBOXYLASE INHIBITOR; LEVODOPA; PERGOLIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MYOCLONUS; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SLEEP;

EID: 0031779237     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050055     Document Type: Article

References (12)

1. Allen RP, Earley CJ (1996) Augmentation of the restless legs syndrome with carbidopa/ levodopa. Sleep 19(3): 205-213
2. Askenasy JJM, Yahr MD (1984) Suppression of REM rebound by pergolide. J Neural Transm 70: 151-159
3. Bunney BS, Walters JR, Roth RH, Aghajanian G (1973) Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560-571
4. Engber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D1 and D2 dopamine agonists. Eur J Pharmacol 168: 291-298
5. Juncos JL, Engber TM, Raisman R, Susel Z, Thibaut F, Ploska A, Agid Y, Chase TN (1989) Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25: 473-478
6. Mitler MM, Browman CP, Menn SJ, Gujavarty K, Timms RM (1986) Nocturnal mycolonus: treatment efficacy of clonazepam and temazepam. Sleep 9: 385-392
7. Monti JM, Hawkins M, Jantos H, D'Angelo L, Fernàndez M (1988) Biphasic effects of dopamine D2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacol 95: 395-400
8. Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Brain Information Service/Brain Research Institute, UCLA, Los Angeles
9. Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E (1995) Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS). J Neural Transm [Gen Sect] 99: 187-193
10. Staedt J, Stoppe G, Riemann H, Hajak G, Rüther E, Riederer P (1996) Lamotrigine in the treatment of Nocturnal Myoclonus Syndrome (NMS): two case reports. J Neural Transm 103: 355-361
11. Staedt J, Waßmuth F, Ziemann U, Hajak G, Rüther E, Stoppe G (1997) Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa. J Neural Transm 104: 461-468
12. Weick BG, Engber TM, Susel Z, Chase TN, Walters JR (1990) Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopaminelesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Res 523: 16-22